Symposien

IP, Market Value and Start-ups

The proposal of SPRIND (German Agency for Disruptive Innovations) to license IP for virtual shares as a standard procedure for start-ups has not met with universal approval. How applicable is such a model to biotechnology start-ups, and can a one-size-fits-all approach really do away with defining market value and negotiating fair and reasonable IP terms? After a keynote, representatives of SPRIND, universities and technology transfer experts will share their experience and discuss their various approaches to start-up creation.

Moderation

Dr. Birgit Kerber

Dr. Birgit Kerber

EMBLEM

Dr. Thomas Hanke

Dr. Thomas Hanke

Evotec

Podium

Dr. Regina Hodits

Dr. Regina Hodits

Wellington Partners

Dr. Nicolas Krink

Dr. Nicolas Krink

SPRIND

Dr. Andrea Schmoll

Dr. Andrea Schmoll

Osborne Clarke

Dr. Rainer Wessel

Dr. Rainer Wessel

German Cancer Research Center (DKFZ)